## ABBV: AbbVie Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.6% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($220.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. The Truth About AbbVie Inc: Is ABBV the Sleeper Stock Gen Z Is Sleeping On?**
- Source: AD HOC NEWS | 20251231T140713 | Somewhat-Bullish | Relevance: 100%
- AbbVie Inc. (ABBV) is presented as a "sleeper stock" that Gen Z investors might be overlooking, despite its strong dividend yield and defensive characteristics. While not a viral stock like meme shares or AI companies, ABBV offers consistent income and portfolio stability, making it attractive for long-term investors focused on dividend growth rather than quick gains, weighing its established immunology pipeline against the “Humira hangover”.

**2. AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share**
- Source: Insider Monkey | 20251231T163225 | Bullish | Relevance: 100%
- AbbVie (ABBV) is maintaining its immunology dominance, with analysts downplaying the competitive threat from J&J’s Tremfya to its Skyrizi market share. The company reported strong Q3 2025 net revenues of ~$15.8 billion, driven by growth in newer immunology and neuroscience treatments, particularly Skyrizi and Rinvoq, which cushioned the decline of Humira. Analysts from Morgan Stanley and HSBC have raised price targets for ABBV, citing strong growth momentum and consistent operational execution.

**3. The Truth About AbbVie Inc: Is ABBV the Sleeper Stock Gen Z Is Sleeping On?**
- Source: AD HOC NEWS | 20251231T143057 | Somewhat-Bullish | Relevance: 100%
- This article explores whether AbbVie Inc. (ABBV) is a valuable "sleeper stock" overlooked by younger generations favoring trend-driven investments. It delves into ABBV's strong dividend yield, its transition away from reliance on Humira with new growth drugs like Skyrizi and Rinvoq, and its competitive standing against other pharmaceutical giants. The piece concludes that ABBV is a strong contender for long-term investors seeking steady income and healthcare exposure, despite not being a volatile, "viral" stock.

**4. VIRGINIA RETIREMENT SYSTEMS ET Al Grows Stake in AbbVie Inc. $ABBV**
- Source: MarketBeat | 20251231T115821 | Bullish | Relevance: 100%
- VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in AbbVie Inc. by 48.9% in the third quarter, acquiring 96,200 additional shares to reach a total of 293,111 shares valued at $67.9 million. This move comes as AbbVie reported strong Q3 earnings, beating analyst estimates with $1.86 EPS and $15.78 billion in revenue, prompting an increase in its quarterly dividend to $1.73. Institutional ownership of AbbVie stands at 70.23%, with major firms like Vanguard and Geode Capital Management also increasing their positions, and analysts maintaining a "Moderate Buy" consensus with a $245.84 target price.

**5. AbbVie Inc. $ABBV Shares Acquired by Smith Salley Wealth Management**
- Source: MarketBeat | 20251231T113621 | Bullish | Relevance: 100%
- Smith Salley Wealth Management increased its holdings in AbbVie Inc. by 3.2% in the third quarter, now owning 158,917 shares valued at $36.8 million. Other institutional investors have also adjusted their stakes, with hedge funds and institutional investors collectively owning 70.23% of the company's stock. AbbVie recently reported strong earnings, beating consensus estimates, and announced an increased quarterly dividend of $1.73 per share, representing a 3.0% yield.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $269 | $261 | +3% |
| 2025-12-10 | HSBC | $265 | $225 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | HSBC | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.1% (+0.2%)
- Blackrock Inc.: 8.3% (-1.0%)
- JPMORGAN CHASE & CO: 6.4% (+97.6%)
- State Street Corpora: 4.5% (-0.2%)
- Morgan Stanley: 2.4% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.41 indicates undervaluation relative to growth. Forward P/E 16.0x attractive for 34% earnings growth. Quality metrics strong (ROE 138%). Balance sheet: $6.5B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $403.8B |
| Beta | 0.35 |
| 52W Range | $164.39 - $244.81 |
| Short Interest | 1.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.41 |
| Forward P/E | 16.0 |
| Current P/E | 21.5 |
| YoY Growth | 33.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 stable at 0.6% (minimal 5-day change). Below STRENGTH zone by 2.4pp (needs >3.0% for momentum thesis). MRS_5 at 0.4% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.62% (CS: 79) | Neutral |
| RSI_14 | 52.3 | Neutral |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 1.109x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $228.47
- **Stop Loss:** $220.63 (3.4% risk)
- **Target:** $236.31 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 183
- **Position Value:** $41,810.01
- **Portfolio %:** 41.81%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-06 (Est: $3.35)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $1.86 | +4.2% |
| 2025Q2 | $2.91 | $2.97 | +2.1% |
| 2025Q1 | $2.40 | $2.46 | +2.6% |
| 2024Q4 | $2.12 | $2.16 | +1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*